Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Diseases 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × TAS4464 × Clear all
NCT02978235 2024-09-05

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Taiho Oncology, Inc.

Phase 1 Terminated
11 enrolled
LymphoidPlasma cell

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡